Full Text Journal Articles by
Author Marc C Gittelman

Advertisement

Find full text journal articles








Reply by Authors.

Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Marc Pliskin, J Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Nicholas N Tadros, Steven N Gange, Claus G Roehrborn,

J Urol (The Journal of urology)
[2021, :101097JU000000000000177803]

Cited: 0 times

View full text PDF listing >>



Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Marc Pliskin, J Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Nicholas N Tadros, Steven N Gange, Claus G Roehrborn,

<h4>Purpose</h4>We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia.<h4>Materials and methods</h4>A total of 197 subjects <u>></u>50 years of age with International Prostate Symptom Score ≥13, maximum flow ... Read more >>

J Urol (The Journal of urology)
[2021, :101097JU0000000000001778]

Cited: 0 times

View full text PDF listing >>



Advertisement

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.

Ronald S Swerdloff, Christina Wang, William B White, Jed Kaminetsky, Marc C Gittelman, James A Longstreth, Robert E Dudley, Theodore M Danoff,

<h4>Context</h4>A novel formulation of oral testosterone (T) undecanoate (TU) was evaluated in a phase 3 clinical trial.<h4>Objective</h4>Determine efficacy, short-term safety, and alignment of new oral TU formulation with current US approval standards for T replacement therapy.<h4>Design</h4>Randomized, active-controlled, open-label study.<h4>Setting and patients</h4>Academic and private clinical practice sites; enrolled patients were clinically ... Read more >>

J Clin Endocrinol Metab (The Journal of clinical endocrinology and metabolism)
[2020, 105(8):]

Cited: 2 times

View full text PDF listing >>



Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.

Claus G Roehrborn, Steven N Gange, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Michael Rousseau, J Randolf Beahrs, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Thayne R Larson, Christopher M Dixon, Kevin T McVary,

<h4>Purpose</h4>We report 2-year outcomes of a multicenter randomized controlled trial plus 1-year results of a crossover trial after treatment with convective radiofrequency water vapor thermal energy for lower urinary tract symptoms due to benign prostatic hyperplasia.<h4>Materials and methods</h4>A total of 197 men at least 50 years old with I-PSS (International ... Read more >>

J Urol (The Journal of urology)
[2017, 197(6):1507-1516]

Cited: 18 times

View full text PDF listing >>



Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study".

Kevin T McVary, Steven N Gange, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Michael Rousseau, J Randolf Beahrs, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Thayne R Larson, Christopher M Dixon, Claus G Roehrborn,

J Sex Med (The journal of sexual medicine)
[2016, 13(6):936-937]

Cited: 0 times

View full text PDF listing >>



Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study.

Kevin T McVary, Steven N Gange, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Michael Rousseau, J Randolf Beahrs, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Thayne R Larson, Christopher M Dixon, Claus G Roehrborn,

<h4>Introduction</h4>Most surgical treatments for male lower urinary tract symptoms and benign prostatic hyperplasia affect erectile and ejaculatory functions negatively, leading to patient dissatisfaction.<h4>Aim</h4>To determine whether water vapor thermal therapy, when conducted in a randomized controlled trial, would significantly improve lower urinary tract symptoms secondary to benign prostatic hyperplasia and urinary ... Read more >>

J Sex Med (The journal of sexual medicine)
[2016, 13(6):924-933]

Cited: 22 times

View full text PDF listing >>



Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Kevin T McVary, Steven N Gange, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Michael Rousseau, J Randolf Beahrs, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Thayne R Larson, Christopher M Dixon, Claus G Roehrborn,

<h4>Purpose</h4>This report reveals the results of a multicenter, randomized, controlled study using transurethral prostate convective water vapor thermal energy to treat lower urinary tract symptoms associated with benign prostatic hyperplasia.<h4>Materials and methods</h4>Men 50 years old or older with an International Prostate Symptom Score of 13 or greater, maximum flow rate ... Read more >>

J Urol (The Journal of urology)
[2016, 195(5):1529-1538]

Cited: 39 times

View full text PDF listing >>



Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

Leonard S Marks, Marc C Gittelman, Lawrence A Hill, Weining Volinn, Gary Hoel,

<h4>Purpose</h4>We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies.<h4>Materials and methods</h4>Men 50 years or older with an International Prostate Symptom Score of 13 or greater and peak urinary flow rate of 4 to 15 ml per ... Read more >>

J Urol (The Journal of urology)
[2013, 189(1 Suppl):S122-8]

Cited: 9 times

View full text PDF listing >>



PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

Marc C Gittelman, Bernard Hertzman, James Bailen, Thomas Williams, Isaac Koziol, Ralph Jonathan Henderson, Mitchell Efros, Mohamed Bidair, John F Ward,

<h4>Purpose</h4>We evaluated the clinical usefulness of the PROGENSA® PCA3 Assay for predicting repeat prostate biopsy outcome.<h4>Materials and methods</h4>Men with at least 1 prior negative prostate biopsy who were scheduled for repeat prostate biopsy based on best clinical judgment were enrolled at 14 centers. Whole blood and post-digital rectal examination urine ... Read more >>

J Urol (The Journal of urology)
[2013, 190(1):64-69]

Cited: 53 times

View full text PDF listing >>



Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.

Neal Shore, Michael S Cookson, Marc C Gittelman,

<h4>Objective</h4>To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study.<h4>Patients and methods</h4>Men with advanced prostate cancer and a clinical response to 52 weeks of treatment with the histrelin implant. Implants were placed annually. The primary efficacy variable was achievement of serum ... Read more >>

BJU Int (BJU international)
[2012, 109(2):226-232]

Cited: 9 times

View full text PDF listing >>



Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies.

Marc C Gittelman, Leonard S Marks, Lawrence A Hill, Weining Volinn, Gary Hoel,

<h4>Purpose</h4>Pooled results from 2 randomized, placebo-controlled, US phase III studies (NCT00224107, NCT00224120) showed that silodosin, a uroselective α-blocker, significantly improved International Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic hyperplasia (BPH). This analysis evaluated the effect of silodosin on each symptom assessed by IPSS questionnaire.<h4>Materials and methods</h4>Study participants ... Read more >>

Open Access J Urol (Open access journal of urology)
[2010, 3:1-5]

Cited: 1 time

View full text PDF listing >>



Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study.

Leonard S Marks, Marc C Gittelman, Lawrence A Hill, Weining Volinn, Gary Hoel,

<h4>Objectives</h4>To evaluate long-term safety of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia (BPH).<h4>Methods</h4>Patients enrolled in this open-label extension study had completed 1 of 2 identical double-blind, placebo-controlled 12-week studies of silodosin treatment for symptomatic BPH. For 40 weeks, patients received silodosin ... Read more >>

Urology (Urology)
[2009, 74(6):1318-1322]

Cited: 34 times

View full text PDF listing >>



Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

Leonard S Marks, Marc C Gittelman, Lawrence A Hill, Weining Volinn, Gary Hoel,

<h4>Purpose</h4>We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies.<h4>Materials and methods</h4>Men 50 years or older with an International Prostate Symptom Score of 13 or greater and peak urinary flow rate of 4 to 15 ml per ... Read more >>

J Urol (The Journal of urology)
[2009, 181(6):2634-2640]

Cited: 90 times

View full text PDF listing >>



Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Matthew R Smith, Fairooz Kabbinavar, Fred Saad, Arif Hussain, Marc C Gittelman, David L Bilhartz, Chris Wynne, Robin Murray, Norman R Zinner, Claude Schulman, Ronald Linnartz, Ming Zheng, Carsten Goessl, Yong-Jiang Hei, Eric J Small, Richard Cook, Celestia S Higano,

<h4>Purpose</h4>To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy.<h4>Patients and methods</h4>The 201 patients in this report were the placebo control group from an aborted randomized controlled trial to evaluate the effects of zoledronic acid on time to first bone metastasis in ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2005, 23(13):2918-2925]

Cited: 219 times

View full text PDF listing >>



Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

Claus G Roehrborn, Reginald Bruskewitz, J Curtis Nickel, John D McConnell, Brian Saltzman, Marc C Gittelman, Gholem H Malek, James E Gottesman, Shilaja Suryawanshi, Jennifer Drisko, Alan Meehan, Joanne Waldstreicher, ,

PURPOSE: We determined the effect of long-term treatment with finasteride on the incidence of acute urinary retention (AUR) and benign prostatic hyperplasia (BPH) related surgery in men with BPH. MATERIALS AND METHODS: The Proscar (Merck and Co., Inc., Whitehouse Station, New Jersey) Long-Term Efficacy and Safety Study (PLESS) was comprised ... Read more >>

J Urol (The Journal of urology)
[2004, 171(3):1194-1198]

Cited: 39 times

View full text PDF listing >>



Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.

Roger R Dmochowski, Peter K Sand, Norman R Zinner, Marc C Gittelman, G Willy Davila, Steven W Sanders, ,

OBJECTIVES:To compare the efficacy and safety of an oxybutynin transdermal delivery system (OXY-TDS) and oral, long-acting tolterodine (TOL-LA) with placebo in previously treated patients with urge or mixed urinary incontinence. METHODS:After withdrawal of their current antimuscarinic therapy, 361 adult patients were randomized to 12 weeks of double-blind, double-dummy treatment with ... Read more >>

Urology (Urology)
[2003, 62(2):237-242]

Cited: 153 times

View full text PDF listing >>



Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.

Roger R Dmochowski, G Willy Davila, Norman R Zinner, Marc C Gittelman, Daniel R Saltzstein, Sydney Lyttle, Steven W Sanders, ,

<h4>Purpose</h4>We evaluated the efficacy and safety of an oxybutynin transdermal delivery system (TDS) in a general population of patients with overactive bladder and urge or mixed urinary incontinence.<h4>Materials and methods</h4>Following symptom stabilization or treatment withdrawal 520 adult patients were randomized to 12 weeks of double-blind daily treatment with 1.3, 2.6 ... Read more >>

J Urol (The Journal of urology)
[2002, 168(2):580-586]

Cited: 122 times

View full text PDF listing >>





Advertisement

Disclaimer
0.8853 s